secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2023-01-25T23:59:59+00:00
Accession:  0001193125-23-014850
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA lifts full clinical hold on Inhibikase's IkT-148009 for Parkinson's; Phase 2a trial restarting
--------------------------------------------------------------------------------

- FDA lifted full clinical hold on IkT-148009; Phase 2a 201 trial resumes at 50 and 100 mg doses.
- Company will measure safety and steady-state PK of 200 mg in 6 healthy subjects before PD patient dosing.
- Expanded ocular monitoring includes cornea/lens; no ocular pathology observed to date.
- Inhibikase intends to seek lift of clinical hold on its Multiple System Atrophy (MSA) program.
- Publication in Science Translational Medicine shows IkT-148009 halts neurodegeneration and reduces alpha-synuclein pathology in mouse models.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312523014850/0001193125-23-014850-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312523014850/d439029d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-014850

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer